Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Dr Pedro Rocha speak to ecancer about results from the phase 1b DeLLphi-308 study evaluating subcutaneous tarlatamab in patients with previously treated extensive-stage small cell lung cancer.

He reports that the selected 15 mg subcutaneous dose achieved comparable drug exposure to the established intravenous regimen, while offering the potential for more convenient administration.

Dr Rocha explains that treatment was generally well tolerated, with cytokine release syndrome predominantly grade 1 and no grade 3 or higher events. This safety profile supported the elimination of mandatory post-dose monitoring during the study.

Preliminary efficacy was also observed, with an objective response rate of 30% at the selected 15 mg dose, supporting further evaluation of subcutaneous tarlatamab as a potentially more convenient treatment approach for SCLC.